New Jersey Right to Try-Plus Act allows terminally ill patients access to investigational and off-label treatments.
The New Jersey Right to Try-Plus Act permits terminally ill patients to request access to investigational drugs, biological products, and devices that have not been approved by the FDA, as well as off-label treatments using FDA-approved drugs, biological products, and devices. Patients must have a terminal illness, consider all FDA-approved treatment options, receive a prescription from a licensed physician, and provide informed consent.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.